AnalystsMarc GoodmanMarc Goodman's Stock Forecasts
AnalystsMarc Goodman
Analyst Ranking
Top 9%
#415 out of 4873 analysts
Average Return
+14.62%
Win Rate
52%43 out of 83
Risk vs Reward
Poor
Good
Marc Goodman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Avadel Pharmaceuticals PLCAVDL | +453.60% | $2.50 | $13.84 | 2022-05-26 - 2023-05-26 | Buy |
Evolus IncEOLS | +226.17% | $3.86 | $12.59 | 2020-04-02 - 2021-04-01 | Buy |
Belite Bio IncBLTE | +159.67% | $18.62 | $48.35 | 2023-07-25 - 2024-07-25 | Buy |
Biohaven LtdBHVN | +157.93% | $18.73 | $48.31 | 2023-01-23 - 2024-01-23 | Buy |
Amylyx Pharmaceuticals IncAMLX | +115.64% | $12.85 | $27.71 | 2022-03-30 - 2023-03-30 | Buy |
Marc Goodman Analyst Color
Get additional color on Marc Goodman's coverage of popular stocks
Marc Goodman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Amylyx Pharmaceuticals IncAMLX | 4 | Buy | $10.00 | +118.34% | Upgrades | 2 days ago |
Opthea LtdOPT | 2 | Hold | $1.00 | -70.67% | Downgrades | a month ago |
Axsome Therapeutics IncAXSM | 6 | Buy | $150.00 | +37.79% | Maintains | 3 months ago |
Relmada Therapeutics IncRLMD | 3 | Hold | $1.00 | +175.48% | Downgrades | 5 months ago |
Biohaven LtdBHVN | 2 | Buy | $60.00 | +196.30% | Maintains | 8 months ago |
Lenz Therapeutics IncLENZ | 1 | Buy | $32.00 | N/A | Initiates Coverage On | a year ago |
Belite Bio IncBLTE | 1 | Buy | $25.00 | N/A | Initiates Coverage On | 2 years ago |
Aptinyx IncAPTX | 4 | Hold | $0.50 | N/A | Downgrades | 2 years ago |
Denali Therapeutics IncDNLI | 1 | Buy | $50.00 | N/A | Initiates Coverage On | 2 years ago |
Marinus Pharmaceuticals IncMRNS | 4 | Buy | $23.00 | N/A | Maintains | 2 years ago |
Evolus IncEOLS | 2 | Buy | $20.00 | N/A | Maintains | 2 years ago |
Satsuma Pharmaceuticals IncSTSA | 4 | Hold | $1.00 | N/A | Downgrades | 2 years ago |
Neurocrine Biosciences IncNBIX | 3 | Hold | $115.00 | N/A | Maintains | 3 years ago |
Biogen IncBIIB | 10 | Buy | $310.00 | N/A | Maintains | 3 years ago |
Climb Bio IncCLYM | 4 | Buy | $4.00 | N/A | Maintains | 3 years ago |
Avadel Pharmaceuticals PLCAVDL | 2 | Buy | $12.00 | N/A | Maintains | 3 years ago |
Xenon Pharmaceuticals IncXENE | 4 | Buy | $46.00 | N/A | Maintains | 3 years ago |
Karuna Therapeutics IncKRTX | 2 | Buy | $270.00 | N/A | Maintains | 3 years ago |
Acadia Pharmaceuticals IncACAD | 3 | Buy | $21.00 | N/A | Maintains | 3 years ago |
Jazz Pharmaceuticals PLCJAZZ | 5 | Buy | $210.00 | N/A | Maintains | 3 years ago |
Sage Therapeutics IncSAGE | 4 | Hold | $40.00 | N/A | Maintains | 3 years ago |
Ac Immune SaACIU | 2 | Buy | $10.00 | N/A | Maintains | 3 years ago |
Biohaven Pharmaceutical Holding Co LtdBHVN1 | 3 | Hold | N/A | N/A | Downgrades | 3 years ago |
Alkermes PLCALKS | 4 | Hold | $27.00 | N/A | Maintains | 3 years ago |
Intra Cellular Therapies IncITCI | 3 | Buy | $70.00 | N/A | Maintains | 3 years ago |
Disc Medicine IncIRON | 2 | Hold | $2.00 | N/A | Downgrades | 3 years ago |
Aldeyra Therapeutics IncALDX | 2 | Buy | $15.00 | N/A | Maintains | 3 years ago |
Zogenix IncZGNX | 2 | Buy | $32.00 | N/A | Maintains | 3 years ago |
Calcimedica IncCALC | 3 | Hold | $5.00 | N/A | Downgrades | 4 years ago |
Gw Pharmaceuticals PLCGWPH | 1 | Hold | $220.00 | N/A | Downgrades | 4 years ago |
Allergan PLCAGN | 2 | Strong Buy | $173.00 | N/A | Maintains | 6 years ago |
Abbvie IncABBV | 3 | Hold | $91.00 | N/A | Assumes | 6 years ago |
Ulta Beauty IncULTA | 3 | Strong Buy | $335.00 | N/A | Maintains | 6 years ago |
Bristol Myers Squibb CoBMY | 2 | Hold | N/A | N/A | Downgrades | 7 years ago |
Merck & Co IncMRK | 2 | Strong Buy | $67.00 | N/A | Maintains | 8 years ago |
Impax Laboratories IncIPXL | 1 | Strong Sell | $16.00 | N/A | Maintains | 8 years ago |
Sucampo Pharmaceuticals IncSCMP | 1 | Strong Buy | $15.00 | N/A | Maintains | 8 years ago |
Perrigo Co PLCPRGO | 1 | Strong Buy | $98.00 | N/A | Maintains | 8 years ago |
Neos Therapeutics IncNEOS | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.